Brainstorm Cell Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.3
- Today's High:
- $1.41
- Open Price:
- $1.37
- 52W Low:
- $1.0854
- 52W High:
- $4.7
- Prev. Close:
- $1.34
- Volume:
- 252231
Company Statistics
- Market Cap.:
- $117.04 million
- Book Value:
- -0.126
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -90.97%
- Return on Equity TTM:
- -497.07%
Company Profile
Brainstorm Cell Therapeutics Inc had its IPO on 2003-08-28 under the ticker symbol BCLI.
The company operates in the Healthcare sector and Biotechnology industry. Brainstorm Cell Therapeutics Inc has a staff strength of 41 employees.
Stock update
Shares of Brainstorm Cell Therapeutics Inc opened at $1.37 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.3 - $1.41, and closed at $1.34.
This is a 0% increase from the previous day's closing price.
A total volume of 252,231 shares were traded at the close of the day’s session.
In the last one week, shares of Brainstorm Cell Therapeutics Inc have slipped by -17.79%.
Brainstorm Cell Therapeutics Inc's Key Ratios
Brainstorm Cell Therapeutics Inc has a market cap of $117.04 million, indicating a price to book ratio of 47.3885 and a price to sales ratio of 0.
In the last 12-months Brainstorm Cell Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-24220000. The EBITDA ratio measures Brainstorm Cell Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Brainstorm Cell Therapeutics Inc’s operating margin was 0% while its return on assets stood at -90.97% with a return of equity of -497.07%.
In Q1, Brainstorm Cell Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Brainstorm Cell Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.69 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Brainstorm Cell Therapeutics Inc’s profitability.
Brainstorm Cell Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.4294. Its price to sales ratio in the trailing 12-months stood at 0.
Brainstorm Cell Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $7.87 million
- Total Liabilities
- $10.42 million
- Operating Cash Flow
- $2.01 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Brainstorm Cell Therapeutics Inc ended 2024 with $7.87 million in total assets and $0 in total liabilities. Its intangible assets were valued at $7.87 million while shareholder equity stood at $-4840000.00.
Brainstorm Cell Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $10.42 million in other current liabilities, 12000.00 in common stock, $-202880000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $2.02 million and cash and short-term investments were $2.23 million. The company’s total short-term debt was $1,389,000 while long-term debt stood at $0.
Brainstorm Cell Therapeutics Inc’s total current assets stands at $2.93 million while long-term investments were $0 and short-term investments were $206000.00. Its net receivables were $44000.00 compared to accounts payable of $7.80 million and inventory worth $0.
In 2024, Brainstorm Cell Therapeutics Inc's operating cash flow was $2.01 million while its capital expenditure stood at $0.
Comparatively, Brainstorm Cell Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.34
- 52-Week High
- $4.7
- 52-Week Low
- $1.0854
- Analyst Target Price
- $15
Brainstorm Cell Therapeutics Inc stock is currently trading at $1.34 per share. It touched a 52-week high of $4.7 and a 52-week low of $4.7. Analysts tracking the stock have a 12-month average target price of $15.
Its 50-day moving average was $1.69 and 200-day moving average was $2.09 The short ratio stood at 11.94 indicating a short percent outstanding of 0%.
Around 2400.4% of the company’s stock are held by insiders while 1062.3% are held by institutions.
Frequently Asked Questions About Brainstorm Cell Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer’s disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.